cephalexin

Product NDC: 33261-020
11-digit product format: 332610020
Labeler code: 33261
Product ID: 33261-020_9e4f9fd2-cd74-4527-8b28-4688f72cdf6f
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: cephalexin
Dosage form: CAPSULE
Route: ORAL
Labeler: Aidarex Pharmaceuticals LLC
Application: ANDA062791
Marketing category: ANDA
Marketing start: 2010-06-21
Marketing end: 0000-00-00
Substance: CEPHALEXIN ANHYDROUS
Active strength: 500 mg/1
Pharmacologic classes: Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
NDC exclude flag: No
Listing certified through: 2019-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 6 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	33261-020		I	Inactivated by FDA	2026-08-03
excluded package	package	33261-020	33261-020-20	I	Inactivated by FDA	2026-08-03
excluded package	package	33261-020	33261-020-28	I	Inactivated by FDA	2026-08-03
excluded package	package	33261-020	33261-020-30	I	Inactivated by FDA	2026-08-03
excluded package	package	33261-020	33261-020-40	I	Inactivated by FDA	2026-08-03
excluded package	package	33261-020	33261-020-88	I	Inactivated by FDA	2026-08-03

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 3 · 126 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	33261-020-20	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	33261-020-88	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	33261-020-40	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	33261-020-28	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	33261-020-30	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	33261-020-20	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	33261-020-88	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	33261-020-40	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	33261-020-28	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	33261-020-30	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	33261-020-20	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	33261-020-88	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	33261-020-40	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	33261-020-28	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	33261-020-30	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	33261-020-20	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	33261-020-88	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	33261-020-40	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	33261-020-28	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	33261-020-30	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	33261-020-20	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	33261-020-88	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	33261-020-40	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	33261-020-28	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	33261-020-30	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	33261-020-20	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	33261-020-88	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	33261-020-40	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	33261-020-28	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	33261-020-30	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	33261-020-20	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	33261-020-88	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	33261-020-40	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	33261-020-28	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	33261-020-30	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	33261-020-20	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	33261-020-88	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	33261-020-40	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	33261-020-28	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	33261-020-30	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	33261-020-20	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	33261-020-88	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	33261-020-40	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	33261-020-28	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	33261-020-30	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	33261-020-20	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	33261-020-88	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	33261-020-40	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	33261-020-28	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	33261-020-30	`ad56d346431e…`	`cc804d4bbf1e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
A062791-001	CEPHALEXIN	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL			1987-06-11
A062791-002	CEPHALEXIN	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL			1987-06-11

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 82 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	A062791-001	CEPHALEXIN	EQ 250MG BASE	CAPSULE / ORAL	1987-06-11	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	A062791-002	CEPHALEXIN	EQ 500MG BASE	CAPSULE / ORAL	1987-06-11	`782e0a99824c…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2019-09-15 20:21 UTC	2019-09	A062791-001	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	A062791-002	AB	1	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	A062791-001	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	A062791-002	AB	1	`ea99ee380514…`

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
dfa3f520-409c-432e-b6d3-9250d468c772	Product name	1	20250401
64bb7f1a-2c2e-4741-8301-dbfeda7239f6	Product name	1	20190628
398aa563-bb78-fe0f-46a8-757c40ef28bf	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Related label table
NDC	Related label
33261-020-20	Cephalexin Capsules, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, USP and other antibacterial drugs, cephalexin capsule, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
33261-020-28	Cephalexin Capsules, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, USP and other antibacterial drugs, cephalexin capsule, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
33261-020-30	Cephalexin Capsules, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, USP and other antibacterial drugs, cephalexin capsule, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
33261-020-40	Cephalexin Capsules, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, USP and other antibacterial drugs, cephalexin capsule, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
33261-020-88	Cephalexin Capsules, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, USP and other antibacterial drugs, cephalexin capsule, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
33261-020-20	cephalexin	20 in 1 BOTTLE	CAPSULE	20	3
33261-020-28	cephalexin	28 in 1 BOTTLE	CAPSULE	28	3
33261-020-30	cephalexin	30 in 1 BOTTLE	CAPSULE	30	3
33261-020-40	cephalexin	40 in 1 BOTTLE	CAPSULE	40	3
33261-020-88	cephalexin	100 in 1 BOTTLE	CAPSULE	100	3

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
33261-020-20	EA - Each	33261-020	987b3437-fe8d-4f63-ae5c-77f9c2abe558	1	2013-02-13
33261-020-28	EA - Each	33261-020	d4d30441-d077-4896-bed1-e8be2c5d2dcf	1	2013-02-13
33261-020-30	EA - Each	33261-020	414ccb6a-a06a-4f8a-b843-d38f99c64cd4	1	2013-02-13
33261-020-40	EA - Each	33261-020	89ce4477-af2f-4e6a-9e67-a79f950ca554	1	2013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CEPHALEXIN ANHYDROUS	ACTIVE INGREDIENT	5SFF1W6677	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
CEPHALEXIN ANHYDROUS	ACTIVE MOIETY	5SFF1W6677	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
D&C YELLOW NO. 10	INACTIVE INGREDIENT	35SW5USQ3G	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
FD&C BLUE NO. 1	INACTIVE INGREDIENT	H3R47K3TBD	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
FD&C GREEN NO. 3	INACTIVE INGREDIENT	3P3ONR6O1S	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
FD&C YELLOW NO. 6	INACTIVE INGREDIENT	H77VEI93A8	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
GELATIN	INACTIVE INGREDIENT	2G86QN327L	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
SODIUM LAURYL SULFATE	INACTIVE INGREDIENT	368GB5141J	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
33261-020	CEPHALEXIN CAPSULE [AIDAREX PHARMACEUTICALS LLC]	3	Legacy NDC, 5 package rows	20120914_cab0d668-f4a4-4848-ba93-fa2c2246096c.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
5SFF1W6677	CEPHALEXIN ANHYDROUS	15686-71-2	CEPHALEXIN ANHYDROUS
OBN7UDS42Y	CEPHALEXIN	23325-78-2	cephalexin

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
309112	cephalexin 250 MG Oral Capsule	PSN	cab0d668-f4a4-4848-ba93-fa2c2246096c	3
309114	cephalexin 500 MG Oral Capsule	PSN	cab0d668-f4a4-4848-ba93-fa2c2246096c	3
309112	cephalexin 250 MG Oral Capsule	SCD	cab0d668-f4a4-4848-ba93-fa2c2246096c	3
309114	cephalexin 500 MG Oral Capsule	SCD	cab0d668-f4a4-4848-ba93-fa2c2246096c	3
309114	cefalexin (as cefalexin monohydrate) 500 MG Oral Capsule	SY	cab0d668-f4a4-4848-ba93-fa2c2246096c	3
309112	cephalexin (as cephalexin monohydrate) 250 MG Oral Capsule	SY	cab0d668-f4a4-4848-ba93-fa2c2246096c	3

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Status
33261-020-20	33261002020	20 in 1 BOTTLE	Historical
33261-020-28	33261002028	28 in 1 BOTTLE	Historical
33261-020-30	33261002030	30 in 1 BOTTLE	Historical
33261-020-40	33261002040	40 in 1 BOTTLE	Historical
33261-020-88	33261002088	100 in 1 BOTTLE	Historical